20240722 Share repurchase CA
Kurs
+0,32%
Likviditet
2 851 MDKK
Kalender
| Tid* | ||
| 2025-11-05 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-06 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-05 | 07:30 | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | X-dag halvårsutdelning NOVO B 3.5 |
| 2024-08-07 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-02 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-22 | - | X-dag halvårsutdelning NOVO B 6.4 |
| 2024-03-21 | - | Årsstämma |
| 2024-01-31 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-13 | - | Split NOVO B 1:2 |
| 2023-08-18 | - | X-dag halvårsutdelning NOVO B 6 |
| 2023-08-10 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-24 | - | X-dag halvårsutdelning NOVO B 8.15 |
| 2023-03-23 | - | Årsstämma |
| 2023-02-01 | - | Bokslutskommuniké 2022 |
| 2022-11-02 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-12 | - | X-dag halvårsutdelning NOVO B 4.25 |
| 2022-08-04 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-04 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-25 | - | X-dag halvårsutdelning NOVO B 6.9 |
| 2022-03-24 | - | Årsstämma |
| 2022-02-02 | - | Bokslutskommuniké 2021 |
| 2021-11-03 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-16 | - | X-dag halvårsutdelning NOVO B 3.5 |
| 2021-08-05 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-26 | - | X-dag halvårsutdelning NOVO B 5.85 |
| 2021-03-25 | - | Årsstämma |
| 2021-02-03 | - | Bokslutskommuniké 2020 |
| 2020-10-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-14 | - | X-dag halvårsutdelning NOVO B 3.25 |
| 2020-08-06 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-06 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-27 | - | X-dag halvårsutdelning NOVO B 5.35 |
| 2020-03-26 | - | Årsstämma |
| 2020-02-05 | - | Bokslutskommuniké 2019 |
| 2019-11-01 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-08-16 | - | X-dag halvårsutdelning NOVO B 3 |
| 2019-05-03 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-22 | - | X-dag halvårsutdelning NOVO B 5.15 |
| 2019-03-21 | - | Årsstämma |
| 2019-02-01 | - | Bokslutskommuniké 2018 |
| 2018-08-18 | - | X-dag halvårsutdelning NOVO B 3 |
| 2018-08-17 | - | X-dag halvårsutdelning NOVO B 3 |
| 2018-08-08 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-02 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-23 | - | X-dag halvårsutdelning NOVO B 4.85 |
| 2018-03-22 | - | Årsstämma |
| 2018-02-01 | - | Bokslutskommuniké 2017 |
| 2017-11-01 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | X-dag halvårsutdelning NOVO B 3 |
| 2017-08-09 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-03 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-24 | - | X-dag ordinarie utdelning NOVO B 4.60 DKK |
| 2017-03-23 | - | Årsstämma |
| 2017-02-02 | - | Bokslutskommuniké 2016 |
| 2016-10-28 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-12 | - | X-dag halvårsutdelning NOVO B 3 |
| 2016-08-05 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-21 | - | X-dag halvårsutdelning NOVO B 6.4 |
| 2016-03-18 | - | Årsstämma |
| 2016-02-03 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-06 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-30 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-20 | - | X-dag ordinarie utdelning NOVO B 5.00 DKK |
| 2015-03-19 | - | Årsstämma |
| 2015-01-30 | - | Bokslutskommuniké 2014 |
| 2014-10-30 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-07 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-01 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-21 | - | X-dag ordinarie utdelning NOVO B 4.50 DKK |
| 2014-03-20 | - | Årsstämma |
| 2014-02-03 | - | Bokslutskommuniké 2013 |
| 2014-01-02 | - | Split NOVO B 1:5 |
| 2013-10-31 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-08 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-01 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-21 | - | X-dag ordinarie utdelning NOVO B 18.00 DKK |
| 2013-03-20 | - | Årsstämma |
| 2013-02-04 | - | Bokslutskommuniké 2012 |
| 2012-10-31 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-09 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-27 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-22 | - | X-dag ordinarie utdelning NOVO B 14.00 DKK |
| 2012-03-21 | - | Årsstämma |
| 2012-02-02 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-04 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | Kvartalsrapport 2011-Q1 |
| 2011-03-24 | - | X-dag ordinarie utdelning NOVO B 10.00 DKK |
| 2011-03-23 | - | Årsstämma |
| 2011-02-02 | - | Bokslutskommuniké 2010 |
| 2010-03-25 | - | X-dag ordinarie utdelning NOVO B 7.50 DKK |
| 2007-12-03 | - | Split NOVO B 1:2 |
| 2001-04-04 | - | Split NOVO B 1:5 |
| 1997-01-02 | - | Split NOVO B 1:2 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Bagsværd, Denmark, 22 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.2 billion in the period from 7 May 2024 to 5 August 2024.
Since the announcement 15 July 2024, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 1,697,820 | 1,623,066,660 | |
| 15 July 2024 | 36,968 | 980.84 | 36,259,639 |
| 16 July 2024 | 37,000 | 972.00 | 35,963,993 |
| 17 July 2024 | 37,999 | 930.48 | 35,357,395 |
| 18 July 2024 | 37,500 | 916.73 | 34,377,441 |
| 19 July 2024 | 37,500 | 907.23 | 34,020,989 |
| Accumulated under the programme | 1,884,787 | 1,799,046,117 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 11,984,827 B shares of DKK 0.10 as treasury shares, corresponding to 0.3% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 19 July 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 10,619,037 B shares at an average share price of DKK 878.31 per B share equal to a transaction value of DKK 9,326,780,889.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contact for further information.
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
| Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com | Ida Melvold Gjøsund +45 3077 5649 idmg@novonordisk.com |